Greater than two in 5 (42%) or 57.4 million adults underneath 65 with non-public insurance coverage could possibly be eligible underneath medical standards for GLP-1 medicine used to deal with individuals with kind 2 diabetes, weight problems, or extra weight and weight-related well being points, in accordance with a new KFF analysis.
Although solely about 3% of adults with employer protection had a prescription in 2022, demand for and spending on GLP-1 medicine has grown and will proceed to develop. Given the steep prices and excessive demand for these medicine, employers and insurers might proceed to impose extra restrictive eligibility requirements for protection than the medical indications set by the Meals and Drug Administration.
The total evaluation and different information on well being prices can be found on the Peterson-KFF Health System Tracker, a web based info hub devoted to monitoring and assessing the efficiency of the U.S. well being system.
